Applying a common data model to Asian databases for multinational pharmacoepidemiologic studies: opportunities and challenges

Abstract

ObjectiveThe goal of the Asian Pharmacoepidemiology Network is to study the effectiveness and safety of medications commonly used in Asia using databases from individual Asian countries. An efficient infrastructure to support multinational pharmacoepidemiologic studies is critical to this effort.Study design and settingWe converted data from the Japan Medical Data Center database, Taiwan’s National Health Insurance Research Database, Hong Kong’s Clinical Data Analysis and Reporting System, South Korea’s Ajou University School of Medicine database, and the US Medicare 5% sample to the Observational Medical Outcome Partnership common data model (CDM).ResultsWe completed and documented the process for the CDM conversion. The coordinating center and participating sites reviewed the documents and refined the conversions based on the comments. The time required to convert data to the CDM varied widely across sites and included conversion to standard terminology codes and refinements of the conversion based on reviews. We mapped 97.2%, 86.7%, 92.6%, and 80.1% of domestic drug codes from the USA, Taiwan, Hong Kong, and Korea to RxNorm, respectively. The mapping rate from Japanese domestic drug codes to RxNorm (70.7%) was lower than from other countries, and we mapped remaining unmapped drugs to Anatomical Therapeutic Chemical Classification System codes. Because the native databases used international procedure coding systems for which mapping tables have been established, we were able to map >90% of diagnosis and procedure codes to standard terminology codes.ConclusionThe CDM established the foundation and reinforced collaboration for multinational pharmacoepidemiologic studies in Asia. Mapping of terminology codes was the greatest challenge, because of differences in health systems, cultures, and coding systems.

Application of Healthcare ‘Big Data’ in CNS Drug Research: The Example of the Neurological and mental health Global Epidemiology Network (NeuroGEN)

“…Other examples of consortia include the Asian Pharmacoepidemiology Network (AsPEN). AsPEN uses modified distributed networks with a common data structure across databases to allow single analytic programs to be used in each site [61]. Some NeuroGEN investigators are also participating in AsPEN.…”

Application of a Common Data Model (CDM) to rank the paediatric user and prescription prevalence of 15 different drug classes in South Korea, Hong Kong, Taiwan, Japan and Australia: an observational, descriptive study

“…All five countries have universal healthcare systems and none of the databases include information on patients using private healthcare 7. The South Korean and Hong Kong databases, AUSOM and CDARS, collect and archive the EHR of hospital inpatients.…”

“…The Asian Pharmacoepidemiology Network, the first multinational research network in Asia, in collaboration with the Observational Medical Outcome Partnership (OMOP) set up an initiative to convert domestic databases in Asian countries to a Common Data Model (CDM) to offer a multinational research infrastructure to facilitate studies 7 8. We used this network of observational healthcare databases in South Korea, Hong Kong, Taiwan, Japan and Australia to measure and compare the prevalence of drug prescribing in East Asian and Australian children.…”

Feasibility of Using Common Data Model for Orthopedic Research: Analysis of Risk Factors for Periprosthetic Joint Infection after Total Joint Arthroplasty

“…The coding system used for diagnosis in the EMR is an ICD-10 code, whereas the standard concept of CDM for diagnosis is based on the Systematized Nomenclature of Medicine Clinical Terms (SNOMED-CT) [31]. Although most codes was mapped to CDM through the SNOMED-CT, the standard concepts of CDM for drug exposure was based on the RxNorm from the US National Library of Medicine for medications [19]. However, all of codes in EMR were not corresponded to mapping in the CDM version available at the time of this research.…”